Advantage of 188Re-radiopharmaceuticals in hepatocellular cancer and liver metastases.
Liepe
Knut
K
Kotzerke
Jorg
J
Lambert
Bieke
B
D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000378:metabolism* / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007459:Iodized Oil / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000378:metabolism* / Q000532:radiotherapy*; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009928:Organ Specificity; D009942:Organometallic Compounds / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D014018:Tissue Distribution
C498051:188Re-4-hexadecyl-1,2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol lipiodol conjugate; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D007459:Iodized Oil